Skip to main content

Advertisement

Log in

Intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder: pilot study

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

We conducted the first-regenerative medicine cellular therapy for underactive bladder (UAB) in an FDA-approved, compassionate-use IND trial to evaluate treatment safety and potential clinical efficacy of autologous muscle-derived stem cells (AMDC) on a patient with UAB. No study-related adverse events or side effects were reported. In the 1-year follow-up period, the subject denied any gross hematuria, urgency, frequency or infection. A reduction in maximum cystometric capacity from 844 to 663 mL was observed, and the patient was able to void small amounts but continues to require self-catheterization 1 year after AMDC injection. Intradetrusor injection of AMDC is safe, minimally invasive and a promising treatment option for the UAB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Chancellor MB, Diokno A (2014) CURE-UAB: shedding light on the underactive bladder syndrome. Int Urol Nephrol 46(Suppl. 1):S1. doi:10.1007/s11255-014-0789-8

    Article  PubMed  Google Scholar 

  2. Miyazato M, Yoshimura N, Chancellor MB (2013) The other bladder syndrome: underactive bladder. Rev Urol 15(1):11–22

    PubMed Central  PubMed  Google Scholar 

  3. Barendrecht MM, Oelke M, Laguna MP, Michel MC (2007) Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 99(4):749–752. doi:10.1111/j.1464-410X.2006.06742.x

    Article  CAS  PubMed  Google Scholar 

  4. Huard J, Yokoyama T, Pruchnic R, Qu Z, Li Y, Lee JY, Somogyi GT, de Groat WC, Chancellor MB (2002) Muscle-derived cell-mediated ex vivo gene therapy for urological dysfunction. Gene Ther 9(23):1617–1626. doi:10.1038/sj.gt.3301816

    Article  CAS  PubMed  Google Scholar 

  5. Carr LK, Robert M, Kultgen PL, Herschorn S, Birch C, Murphy M, Chancellor MB (2013) Autologous muscle derived cell therapy for stress urinary incontinence: a prospective, dose ranging study. J Urol 189(2):595–601. doi:10.1016/j.juro.2012.09.028

    Article  PubMed  Google Scholar 

  6. Peters KM, Dmochowski RR, Carr LK, Robert M, Kaufman MR, Sirls LT, Herschorn S, Birch C, Kultgen PL, Chancellor MB (2014) Autologous muscle derived cells for treatment of stress urinary incontinence in women. J Urol 192(2):469–476. doi:10.1016/j.juro.2014.02.047

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank the Robert B. and Ann S. Aikens Urology Research Fund for supporting UAB research.

Conflict of interest

Ryan Pruchnic is an employee of Cook Myosite. Michael B. Chancellor has financial interest and a consultant relationship with Cook Myosite. There are no other conflicts of interest related to this publication to report.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael B. Chancellor.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Levanovich, P.E., Diokno, A., Hasenau, D.L. et al. Intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder: pilot study. Int Urol Nephrol 47, 465–467 (2015). https://doi.org/10.1007/s11255-015-0924-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-015-0924-1

Keywords

Navigation